ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress

On December 7, 2021 ISA’s very own Chief Scientific Officer, Cornelis "Kees" Melief, M.D., Ph.D., reported that it will be presenting key learnings in cancer vaccine development in an educational session at the ESMO (Free ESMO Whitepaper) Immune-Oncology Congress 2021, taking place on 8th – 11th December 2021 in Geneva, Switzerland and online (Press release, ISA Pharmaceuticals, DEC 7, 2021, View Source [SID1234596554]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key learnings include:

Direct correlation between strength of cancer vaccine-induced immune response and clinical response
Combination therapy of cancer vaccine with standard of care and/or checkpoint blockers necessary for improved outcomes in treatment of late stage cancers
Session: New indications in head and neck (H&N) cancer (incl anaplastic thyroid) (ID 8)
Presentation title: HPV vaccination for H&N cancer therapy (ID 39)
Authors: Cornelis J. Melief
Date & Time: Thursday, 9th December, 15:30pm – 15:50pm CET
Locations: Room C

Kees Melief comments: "Our findings consistently highlight the direct correlation between the strength of the vaccine-induced immune response and the subsequent clinical response in patients with metastatic (HPV16+) cancers, including oropharyngeal cancer (OPC). Moreover, we argue that to overcome the hostile tumour microenvironment in late-stage cancer, combination of SLP-based therapies with platin-based standard of care and/or checkpoint blocking (anti-PD1 in particular) is necessary for improved treatment outcomes."

Gerben Moolhuizen, Chief Executive Officer, said: " We recently announced that we received FDA Fast Track designation for our lead product ISA101b, for treatment of recurrent and metastatic HPV16+ OPC. We are proud to be presenting our compelling findings in cancer vaccine combination therapy development at this influential medical conference, following the start of a next phase 2 clinical trial investigating the combination of ISA101b and Libtayo in advanced HPV16 positive OPC."